TG Therapeutics, Inc. (NASDAQ:TGTX) Shares Sold by Alliancebernstein L.P.

Alliancebernstein L.P. trimmed its position in TG Therapeutics, Inc. (NASDAQ:TGTX) by 10.1% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 174,020 shares of the biopharmaceutical company’s stock after selling 19,550 shares during the period. Alliancebernstein L.P. owned about 0.11% of TG Therapeutics worth $5,238,000 at the end of the most recent reporting period.

Other hedge funds have also made changes to their positions in the company. O Shaughnessy Asset Management LLC acquired a new position in TG Therapeutics in the 4th quarter valued at $259,000. Clearbridge Investments LLC acquired a new stake in shares of TG Therapeutics in the fourth quarter valued at about $55,237,000. New Age Alpha Advisors LLC purchased a new position in shares of TG Therapeutics in the fourth quarter worth about $213,000. Norges Bank acquired a new position in TG Therapeutics during the fourth quarter worth about $12,085,000. Finally, Segall Bryant & Hamill LLC grew its stake in TG Therapeutics by 51.8% during the 4th quarter. Segall Bryant & Hamill LLC now owns 79,518 shares of the biopharmaceutical company’s stock valued at $2,393,000 after acquiring an additional 27,128 shares in the last quarter. Institutional investors and hedge funds own 58.58% of the company’s stock.

TG Therapeutics Stock Up 2.0 %

Shares of NASDAQ TGTX opened at $36.71 on Friday. The company has a market capitalization of $5.77 billion, a P/E ratio of -367.06 and a beta of 2.14. The company has a debt-to-equity ratio of 1.27, a current ratio of 4.59 and a quick ratio of 3.91. The company has a 50 day simple moving average of $35.76 and a 200-day simple moving average of $31.39. TG Therapeutics, Inc. has a 1 year low of $12.93 and a 1 year high of $43.32.

TG Therapeutics (NASDAQ:TGTX) last posted its earnings results on Monday, March 3rd. The biopharmaceutical company reported $0.15 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.08 by $0.07. TG Therapeutics had a negative return on equity of 8.32% and a negative net margin of 5.42%. The company had revenue of $108.19 million during the quarter, compared to analysts’ expectations of $100.67 million. On average, equities research analysts predict that TG Therapeutics, Inc. will post 0.08 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on TGTX shares. HC Wainwright reissued a “buy” rating and issued a $55.00 target price on shares of TG Therapeutics in a research note on Tuesday, March 4th. StockNews.com upgraded TG Therapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday, March 4th. Two investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $40.67.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.